Previous close | 34.01 |
Open | 34.35 |
Bid | 34.11 x 200 |
Ask | 34.17 x 400 |
Day's range | 33.88 - 34.45 |
52-week range | 14.31 - 39.79 |
Volume | |
Avg. volume | 462,511 |
Market cap | 1.618B |
Beta (5Y monthly) | 2.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.12 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 35.50 |
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.